Surgical Science Sweden Toekomstige groei
Future criteriumcontroles 4/6
Surgical Science Sweden zal naar verwachting groeien in winst en omzet met respectievelijk 36.1% en 17.8% per jaar. De winst per aandeel zal naar verwachting groeien met 36.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 6.8% zijn.
Belangrijke informatie
36.1%
Groei van de winst
36.1%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 36.6% |
| Inkomstengroei | 17.8% |
| Toekomstig rendement op eigen vermogen | 6.8% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 17 Nov 2024 |
Recente toekomstige groei-updates
Surgical Science Sweden AB (publ) Just Missed EPS By 22%: Here's What Analysts Think Will Happen Next
Aug 25
Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Recent updates
The Price Is Right For Surgical Science Sweden AB (publ) (STO:SUS)
Nov 12Surgical Science Sweden AB (publ) Just Missed EPS By 22%: Here's What Analysts Think Will Happen Next
Aug 25Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21Here's Why Surgical Science Sweden (STO:SUS) Has Caught The Eye Of Investors
Apr 16Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Mar 17Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Is There Now An Opportunity In Surgical Science Sweden AB (publ) (STO:SUS)?
Nov 29Should You Be Adding Surgical Science Sweden (STO:SUS) To Your Watchlist Today?
Oct 07Is Surgical Science Sweden AB (publ) (STO:SUS) Trading At A 39% Discount?
Aug 17With EPS Growth And More, Surgical Science Sweden (STO:SUS) Makes An Interesting Case
Jun 20A Look At The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
May 17Surgical Science Sweden AB (publ) (STO:SUS) Shares Could Be 49% Below Their Intrinsic Value Estimate
Dec 27Is Now The Time To Put Surgical Science Sweden (STO:SUS) On Your Watchlist?
Dec 06Is Now The Time To Look At Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Sep 08We Ran A Stock Scan For Earnings Growth And Surgical Science Sweden (STO:SUS) Passed With Ease
Aug 23Surgical Science Sweden AB (publ) (STO:SUS) Shares Slammed 33% But Getting In Cheap Might Be Difficult Regardless
May 26Here's Why We Think Surgical Science Sweden (STO:SUS) Is Well Worth Watching
Apr 29An Intrinsic Calculation For Surgical Science Sweden AB (publ) (STO:SUS) Suggests It's 44% Undervalued
Feb 20Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jan 11Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Dec 15Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Sep 16Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jul 05Calculating The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Jun 08Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Mar 23Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Mar 02Is Surgical Science Sweden AB (publ)'s (STO:SUS) Shareholder Ownership Skewed Towards Insiders?
Feb 09
Surgical Science Sweden AB (publ)'s (STO:SUS) Stock Is Going Strong: Have Financials A Role To Play?
Jan 01What Does Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Indicate?
Dec 14Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Nov 26Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 1,313 | 363 | 400 | 472 | 6 |
| 12/31/2025 | 1,107 | 256 | 253 | 311 | 6 |
| 12/31/2024 | 895 | 146 | 129 | 181 | 5 |
| 9/30/2024 | 860 | 193 | 73 | 120 | N/A |
| 6/30/2024 | 838 | 198 | 100 | 151 | N/A |
| 3/31/2024 | 842 | 208 | 159 | 206 | N/A |
| 12/31/2023 | 883 | 234 | 194 | 238 | N/A |
| 9/30/2023 | 906 | 253 | 231 | 277 | N/A |
| 6/30/2023 | 901 | 234 | 194 | 234 | N/A |
| 3/31/2023 | 872 | 221 | 140 | 179 | N/A |
| 12/31/2022 | 803 | 188 | 95 | 129 | N/A |
| 9/30/2022 | 750 | 138 | 11 | 38 | N/A |
| 6/30/2022 | 640 | 124 | 61 | 80 | N/A |
| 3/31/2022 | 489 | 101 | 45 | 59 | N/A |
| 12/31/2021 | 367 | 86 | 25 | 39 | N/A |
| 9/30/2021 | 209 | 30 | 59 | 69 | N/A |
| 6/30/2021 | 138 | 21 | 17 | 26 | N/A |
| 3/31/2021 | 122 | 18 | 11 | 20 | N/A |
| 12/31/2020 | 105 | 16 | 15 | 23 | N/A |
| 9/30/2020 | 104 | 14 | 4 | 14 | N/A |
| 6/30/2020 | 112 | 19 | 42 | 54 | N/A |
| 3/31/2020 | 107 | 17 | 37 | 47 | N/A |
| 12/31/2019 | 102 | 13 | 46 | 55 | N/A |
| 9/30/2019 | 88 | 6 | 48 | 56 | N/A |
| 6/30/2019 | 70 | -5 | 6 | 12 | N/A |
| 3/31/2019 | 68 | -5 | 1 | 9 | N/A |
| 12/31/2018 | 66 | -5 | -2 | 7 | N/A |
| 9/30/2018 | 60 | -3 | 0 | 9 | N/A |
| 6/30/2018 | 57 | -6 | N/A | 0 | N/A |
| 3/31/2018 | 56 | -7 | N/A | 8 | N/A |
| 12/31/2017 | 57 | -3 | N/A | 7 | N/A |
| 9/30/2017 | 65 | 4 | N/A | 6 | N/A |
| 6/30/2017 | 60 | 3 | N/A | 12 | N/A |
| 3/31/2017 | 59 | 4 | N/A | 11 | N/A |
| 12/31/2016 | 58 | 3 | N/A | 13 | N/A |
| 12/31/2015 | 52 | 2 | N/A | 8 | N/A |
| 12/31/2014 | 41 | -3 | N/A | N/A | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei SUS ( 36.1% per jaar) ligt boven de spaarquote ( 1.2% ).
Winst versus markt: De winst van SUS ( 36.1% per jaar) zal naar verwachting sneller groeien dan de Swedish markt ( 15% per jaar).
Hoge groeiwinsten: De winst van SUS zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van SUS ( 17.8% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( -0.04% per jaar).
Hoge groei-inkomsten: De omzet van SUS ( 17.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen SUS zal naar verwachting over 3 jaar laag zijn ( 6.8 %).